Locus coeruleus

Orphan designation: rovatirelin Treatment of spinocerebellar ataxia, 11/11/2022 Positive

Retrieved on: 
Tuesday, April 9, 2024
Community, Civil service commission, Spinocerebellar ataxia, Diagnosis, Brain, Prevalence, Disease, BBB, Clinical, Locus coeruleus, Patient, Committee, Thyrotropin-releasing hormone, Spinocerebellar tract, Traffic barrier, EMA, IRIS, Neuron, TRH, Agency, European, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of spinocerebellar ataxia in the European Union on 11 November 2022.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Retrieved on: 
Thursday, February 15, 2024
Therapy, Central nervous system, Schizophrenia, Sleep, DSM-IV codes, Food, Orexin, Behavior, CNS, Locus coeruleus, Motivation, Publication, Somnolence, ACS Medicinal Chemistry Letters, Pharmaceutical industry

BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.

Key Points: 
  • BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.
  • In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist,” the authors describe the development of CVN766 to be over 1,000-fold more selective for the orexin 1 receptor (Ox1R) than the orexin 2 receptor (Ox2R).
  • Dysfunction of this target, Ox1R, is implicated in psychiatric disorders, such as schizophrenia, addictions (including food), and anxieties.
  • “CVN766 has demonstrated high brain permeability, prolonged receptor occupancy, and a pharmacokinetic and safety profile suitable for clinical evaluation across various psychiatric indications,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.

Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI

Retrieved on: 
Wednesday, December 20, 2023
Software, Research, Radiology, Pharmaceutical, Mental Health, Technology, Hospitals, Health Technology, Science, Neurology, Biotechnology, FDA, Health, Psychiatry, Associate, MRI, Locus coeruleus, DSM-IV codes, Physician, Albert Einstein's brain, Hospital, Brain, Doctor of Philosophy, News, PACS, Substantia nigra, Columbia University, Mental Hygiene, University, Biomedicine, CNS, Molecular medicine, Schizophrenia, Assistant, Patient, Diagnosis, Meta-analysis, Neuroscience, Therapy, Algorithm, Automation, Medical imaging

Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.

Key Points: 
  • Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.
  • Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making Terran’s technology the world’s first.
  • NM-101 is a cloud-based analysis platform that is able to seamlessly integrate into existing workflows at hospitals and imaging centers.
  • NM-101 contains algorithms that enabled for the first time the fully automated analysis and the cross-scanner harmonization of neuromelanin MRI scans [8-10,12,13].

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
Monday, November 6, 2023
Post-traumatic stress disorder, FDA, Yale School of Medicine, Opioid use disorder, Standard of care, Intelligence, Government, Public Health Service Act, White House, Dexmedetomidine, Opioid epidemic, BID, Federal Food, Drug, and Cosmetic Act, Federation, Addiction, Xylazine, Psychiatry, COWS, Recreational drug use in Kenya, Locus coeruleus, Pharmacokinetics, OUD, National Institute on Drug Abuse, NIDA, Columbia University, NIH, Safety, Public, American Journal, Minneapolis Veterans Affairs Health Care System, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Fentanyl, Bangladesh Technical Education Board, RTI International, United States Public Health Service, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Key Points: 
  • NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.
  • After this time, BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
  • “With BXCL501, we are excited about the potential to treat patients who are physically dependent on illicit and prescription opioids.
  • In addition to OUD as an indication, BioXcel Therapeutics has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder and alcohol use disorder.

CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference

Retrieved on: 
Thursday, March 30, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Cognition, Clenbuterol, Tremor, International, Depression, PD, Cerebral peduncle, Neurodegenerative disease, Nadolol, Deficit spending, Brain, MCI, Doctor of Philosophy, CNS, Pain, Phase 1, MRI, Arousal, Dysautonomia, HIV disease progression rates, Patient, Pharmacokinetics, Rigidity, Locus coeruleus, Diagnosis, Therapy, Sleep, Memory, Treatment, Pharmaceutical industry

Additionally, the company will present promising Phase 1 data with a second program, CST-2032/CST-107, in healthy participants and patients with mild cognitive impairment (MCI).

Key Points: 
  • Additionally, the company will present promising Phase 1 data with a second program, CST-2032/CST-107, in healthy participants and patients with mild cognitive impairment (MCI).
  • Data will be shared in two oral presentations at the International Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) conference, being held March 28 - April 1, 2023, in Gothenburg, Sweden.
  • The Phase 2 trial was an exploratory, randomized, double-blinded, crossover study in 25 patients with Parkinson’s disease with cognitive deficits.
  • The trial is taking place at 20 centers in the U.S. and New Zealand, with results anticipated later in 2023.

CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment

Retrieved on: 
Monday, December 19, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, PD, Neurodegeneration, RBD, REM, AES, Patient, History, Sleep, Brain, Tremor, REM Sleep Behavior Disorder Screening Questionnaire, Depression, Cognition, Government budget balance, Hyperglycemia, LC, Neuron, Dysautonomia, Diagnosis, Locus coeruleus, Rigidity, Arousal, Conference, Safety, Memory, Union, CNS, Hypokalemia, MCI, Therapy, Pain, Cerebral peduncle, Dream, Metabolism, Autonomic nervous system, Doctor of Philosophy, Perfusion, Pharmaceutical industry

The Phase 2 trial was a randomized, double-blinded, two-period crossover study that enrolled 41 patients with neurodegenerative disease.

Key Points: 
  • The Phase 2 trial was a randomized, double-blinded, two-period crossover study that enrolled 41 patients with neurodegenerative disease.
  • The majority of patients enrolled had Parkinson’s disease, and specifically a history of REM-sleep behavior disorder (PDRBD).
  • Most AEs observed were mild, and there were no serious or severe adverse events attributed to study drug.
  • CuraSen is focused on the development of new treatments for neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and other related orphan conditions.

CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease

Retrieved on: 
Wednesday, September 7, 2022
Professional Services, Health, Neurology, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, HIV disease progression rates, Locus coeruleus, Safety, Heart rate, Neuron, LC, Therapy, Arm, Cognition, Doctor of Philosophy, Brain, Microglia, Memory, Even and odd functions, Pericyte, Union, Cell, Neurodegeneration, MCI, Astrocyte, Patient, Arousal, Perfusion, Biomarker, Mutation, Pharmaceutical industry

The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.

Key Points: 
  • The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.
  • The multi-center trial , which is expected to enroll approximately 40 patients, is being conducted in the United States and New Zealand.
  • CuraSen is focused on the development of new treatments for neurodegenerative diseases, including Parkinsons disease, Alzheimers disease and other related orphan conditions.
  • The trials include patients with mild cognitive impairment, Parkinsons disease with rapid eye movement sleep disorder (PDRBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.

Mom's protective behaviors run deep in the brain, new CSHL research finds

Retrieved on: 
Thursday, March 24, 2022
Cell, Locus coeruleus, Laboratory, NA, Cold, Memory, Multimedia, Neuroscience, Mouse, Cold Spring Harbor Laboratory, SPRING, Sleep, Cancer, Wakefulness, Shea, Autism, LC, Nobel Prize, Biomedical Research, Arousal, Vertebrate, Brain, Disorder, Student, Hypothermia, Neuron, Anxiety, Female, Depression, Education, CSHL, Medical imaging

Neuroscientists at Cold Spring Harbor Laboratory (CSHL) now report this resemblance applies in more ways than one.

Key Points: 
  • Neuroscientists at Cold Spring Harbor Laboratory (CSHL) now report this resemblance applies in more ways than one.
  • "We study pup retrieval because it's very reliable and it's done the same way every time," says Shea.
  • The recordings show LC neurons spike in activity at the exact moment a mom touches a pup to retrieve it.
  • Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology.

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Neurodegeneration, Government budget balance, Cognition, LC, Hippocampus, Safety, Maintenance, Neuron, Parkinson's disease, Circulator, Therapy, MD, Even and odd functions, Perfusion, KUMC, Palpitations, Doctor of Philosophy, Â, Locus coeruleus, Amygdala, Arousal, Patient, Tremor, Research, RBD, Memory, Central nervous system, Thalamus, Heart rate, Clenbuterol, Brain, Pharmaceutical industry, Medical imaging

Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.

Key Points: 
  • Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.
  • Patients who received the initial dose of CST-103 showed significant increases in cerebral blood flow in multiple areas of the brain, including the hippocampus.
  • Increases in cerebral blood flow were consistent one week later in patients who received a second dose of CST-103 as monotherapy.
  • The trials include patients with mild cognitive impairment, Parkinsons disease with rapid eye movement sleep disorder (RBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinson's or Alzheimers disease.